Cite

    Dinesh Khanna et al.. “Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).” Annals of the rheumatic diseases, vol. 77, no. 2, 2018, pp. 212–220. http://access.bl.uk/ark:/81055/vdc_100135140121.0x00005d